

Amendment and Response

Serial No.: 09/937,076

Confirmation No.: 4527

Filed: March 27, 2002

For: METHODS OF USE OF B1-INTEGRIN INHIBITORS

Amendments to the Claims

This listing of claims replaces all prior versions, and listings, of claims in the above-identified application:

1. (currently amended) A method of inhibiting inflammatory leukocyte mediated destruction of tissue in a patient, the method comprising administering to the patient a composition comprising a β 1-integrin inhibitor having consisting of the amino acid sequence QPPRAAIY (SEQ ID NO:3).
2. (cancel)
3. (cancel)
4. (original) The method of claim 1 wherein the composition further includes a pharmaceutically acceptable carrier.
5. (original) The method of claim 1 wherein the inflammatory leukocyte mediated destruction of tissue occurs as a result of CNS ischemic injury, myocardial infarction, angioplasty, surgical incisions, injury-related trauma, transplant reperfusion, or a combination thereof.
6. (original) The method of claim 1 wherein the inflammatory leukocyte mediated destruction of tissue occurs as a result of exposure to heat, cold, light, electricity, chemicals, or a combination thereof.
7. (currently amended) A method of treating a stroke patient, the method comprising administering to the patient a composition comprising a β 1-integrin inhibitor having consisting of the amino acid sequence QPPRAAIY (SEQ ID NO:3) in an amount effective to reduce infarct size, reduce neurological deficit, or both.

Amendment and Response

Serial No.: 09/937,076

Confirmation No.: 4527

Filed: March 27, 2002

For: METHODS OF USE OF B1-INTEGRIN INHIBITORS

-
8. (original) The method of claim 7 wherein the composition is administered locally.
 9. (original) The method of claim 8 wherein the β 1-integrin inhibitor is administered in an amount effective to reduce the infarct size by at least about 80%.
 10. (original) The method of claim 8 wherein the β 1-integrin inhibitor is administered in an amount effective to reduce the neurological deficits by at least about 80%.
 11. (canceled)
 12. (canceled)
 13. (currently amended) A method of treating a patient having a burn-type injury, the method comprising administering a composition comprising a β 1-integrin inhibitor having consisting of the amino acid sequence QPPRAAIY (SEQ ID NO:3) in an amount effective and over a period of time effective to reduce leukocyte-mediated tissue destruction.
 14. (canceled)
 15. (canceled)
 16. (canceled)
 17. (original) The method of claim 13 wherein the period of time is at least 1 hour.
 18. (original) The method of claim 17 wherein the period of time is at least 24 hours.
 19. (original) The method of claim 18 wherein the period of time is at least 48 hours.
 20. (original) The method of claim 13 wherein the composition is administered periodically over a predetermined period of time.

Amendment and Response

Serial No.: 09/937,076

Confirmation No.: 4527

Filed: March 27, 2002

For: METHODS OF USE OF B1-INTEGRIN INHIBITORS

21. (currently amended) A method of treating a burn patient, the method comprising maintaining a composition comprising an effective amount of a β 1-integrin inhibitor ~~having~~ consisting of the amino acid sequence QPPRAAIY (SEQ ID NO:3) on a burn-type injury for a period of time effective to reduce leukocyte-mediated tissue destruction and achieve a desired degree of healing.
22. (canceled)
23. (canceled)
24. (canceled)
25. (currently amended) A method of treating a cancer patient, the method comprising administering to the patient a composition comprising a β 1-integrin inhibitor ~~having~~ consisting of the amino acid sequence QPPRAAIY (SEQ ID NO:3) in an amount effective to inhibit one or more of angiogenesis, cancer cell metastasis, cancer cell motility, or cancer cell migration.
26. (canceled)
27. (canceled)
28. (currently amended) A method of treating a cancer patient, the method comprising administering to the patient a composition comprising a β 1-integrin inhibitor ~~having~~ consisting of the amino acid sequence QPPRAAIY (SEQ ID NO:3) in an amount effective to induce programmed cell death in cancerous tissue or restore normal cellular phenotype to cancerous tissue.
29. (canceled)
30. (canceled)

Amendment and Response

Serial No.: 09/937,076

Confirmation No.: 4527

Filed: March 27, 2002

For: METHODS OF USE OF B1-INTEGRIN INHIBITORS

31. (original) The method of claim 28 further comprising administering a compound that inhibits the enzymatic degradation of the β 1-integrin inhibitor.
32. (currently amended) A method of treating a patient for osteoporosis, the method comprising administering to the patient a composition comprising a β 1-integrin inhibitor having consisting of the amino acid sequence QPPRAAIY (SEQ ID NO:3) in an amount effective to inhibit osteoclast adhesion and bone resorption.
33. (canceled)
34. (canceled)
35. (currently amended) A method of peripheralizing stem cells, the method comprising administering to a patient a composition comprising a β 1-integrin inhibitor having consisting of the amino acid sequence QPPRAAIY (SEQ ID NO:3).
36. (canceled)
37. (canceled)
38. (currently amended) A composition comprising a β 1-integrin inhibitor having consisting of the amino acid sequence QPPRAAIY (SEQ ID NO:3) and a pharmaceutically acceptable carrier.
39. (canceled)
40. (canceled)
41. (new) An isolated β 1-integrin inhibitor consisting of the amino acid sequence QPPRAAIY (SEQ ID NO:3).